Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease
July 17, 2023 07:00 ET
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 17, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that...
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023
July 16, 2023 03:00 ET
|
Acumen Pharmaceuticals, Inc.
Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody ...
Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease During Featured Research Session at the Alzheimer’s Association International Conference (AAIC®) 2023
June 13, 2023 07:00 ET
|
Acumen Pharmaceuticals, Inc.
Topline results for ACU193, the first clinical stage amyloid beta oligomer (AβO)-directed antibody, to provide deeper insight into candidate’s therapeutic potential for the treatment of early...
Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights
May 09, 2023 07:00 ET
|
Acumen Pharmaceuticals, Inc.
Expect to report topline results from INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, in the third quarter of 2023Cash, cash equivalents and marketable...
Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference
May 04, 2023 16:01 ET
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that...
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023
May 02, 2023 16:01 ET
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing...
Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s Disease
March 28, 2023 08:00 ET
|
Acumen Pharmaceuticals, Inc.
Data describe induced pluripotent stem cell (iPSC)-derived excitatory neurons as a human model for assessing selectivity of drug binding to soluble amyloid beta oligomers in Alzheimer’s diseaseResults...
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights
March 27, 2023 07:00 ET
|
Acumen Pharmaceuticals, Inc.
INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, completed enrollment in February 2023 Topline data expected in the third quarter of 2023 Cash, cash...
Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days
March 22, 2023 16:01 ET
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., March 22, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that...
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023
March 20, 2023 16:01 ET
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., March 20, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical developing a novel therapeutic that targets...